Discounted Cash Flow (DCF) Analysis Unlevered
Health Discovery Corporation (HDVY)
$0.0003
0.00 (0.00%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2016 Actual | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 0.04 | 0.04 | 0.04 | 1.52 | 0 | 0.01 | 0.08 | 0.75 | 6.79 | 61.58 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | -1.81 | -0.61 | -0.51 | 1.75 | -0.75 | -1.48 | -13.42 | -121.76 | -1,105.13 | -10,030.12 |
| EBITDA (%) | ||||||||||
| EBIT | -2.07 | -0.87 | -0.77 | 1.60 | -0.75 | -1.52 | -13.79 | -125.11 | -1,135.53 | -10,305.98 |
| EBIT (%) | ||||||||||
| Depreciation | 0.26 | 0.26 | 0.26 | 0.15 | 0 | 0.04 | 0.37 | 3.35 | 30.39 | 275.86 |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2016 Actual | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Total Cash | 0.20 | 0.04 | 0 | 2.30 | 0.92 | 1.68 | 15.22 | 138.16 | 1,253.89 | 11,380.26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | - | - | - | - | - | - | - | - | - | - |
| Account Receivables (%) | ||||||||||
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Inventories (%) | ||||||||||
| Accounts Payable | 0.04 | 0.15 | 0.15 | 0.02 | 0.13 | 0.25 | 2.24 | 20.29 | 184.11 | 1,671 |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 0.0,003 |
|---|---|
| Beta | 1.853 |
| Diluted Shares Outstanding | 397.63 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 4.72% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 12.126 |
| Total Debt | 0.21 |
| Total Equity | 0.12 |
| Total Capital | 0.33 |
| Debt Weighting | 63.99 |
| Equity Weighting | 36.01 |
| Wacc |
Build Up Free Cash
Year A/P | 2016 Actual | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 0.04 | 0.04 | 0.04 | 1.52 | 0 | 0.01 | 0.08 | 0.75 | 6.79 | 61.58 |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -1.81 | -0.61 | -0.51 | 1.75 | -0.75 | -1.48 | -13.42 | -121.76 | -1,105.13 | -10,030.12 |
| EBIT | -2.07 | -0.87 | -0.77 | 1.60 | -0.75 | -1.52 | -13.79 | -125.11 | -1,135.53 | -10,305.98 |
| Tax Rate | -0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| EBIAT | -2.07 | -0.87 | -0.77 | 1.60 | -0.75 | -1.52 | -13.79 | -125.11 | -1,135.53 | -10,306 |
| Depreciation | 0.26 | 0.26 | 0.26 | 0.15 | 0 | 0.04 | 0.37 | 3.35 | 30.39 | 275.86 |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | 0.11 | -0 | -0.13 | 0.11 | 0.12 | 1.99 | 18.05 | 163.83 | 1,486.89 |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| UFCF | - | - | - | - | - | -1.36 | -11.43 | -103.71 | -941.31 | -8,543.25 |
| WACC | ||||||||||
| PV UFCF | -1.27 | -9.91 | -83.74 | -707.74 | -5,981.42 | |||||
| SUM PV UFCF | -6,784.08 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.39 |
| Free cash flow (t + 1) | -8,714.12 |
| Terminal Value | -161,671.92 |
| Present Value of Terminal Value | -113,191.91 |
Intrinsic Value
| Enterprise Value | -119,975.98 |
|---|---|
| Net Debt | -0.70 |
| Equity Value | -119,975.28 |
| Shares Outstanding | 397.63 |
| Equity Value Per Share | -301.72 |